Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 9:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 7,392 matching trials from the live ClinicalTrials.gov search.
Conditions
Neurofibromatosis 1 and 2 (NF1 and NF2)
Interventions
hand-held dynamometer
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
5 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
DPX-Survivac, low dose cyclophosphamide (oral)
Biological · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Buffalo, New York • Mineola, New York • Durham, North Carolina + 2 more
Conditions
COPD
Interventions
QBM076, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Healthy Volunteers
Interventions
ELA026
Drug
Lead sponsor
Electra Therapeutics Inc.
Industry
Eligibility
19 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

NCT02210247
Conditions
Healthy Volunteers
Interventions
EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor
Interventions
AFM24, SNK01
Drug · Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois
Conditions
Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
Interventions
ANS014004 + PLB1004, ANS014004 + Osimertinib
Drug
Lead sponsor
Beijing Pearl Biotechnology Limited Liability Company
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Results available

A Study of TAS-120 in Patients With Advanced Solid Tumors

NCT02052778
Conditions
Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer
Interventions
Futibatinib
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
26
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
GRT6019
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Completed No phase listed Observational Results available

Hemosonics- VCU Cardiac Surgery Clinical Study

NCT02392247
Conditions
Cardiopulmonary Bypass
Interventions
Coagulation function
Device
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 89 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Interventions
Ivonescimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Osteoarthritis, Knee
Interventions
PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Interventions
Vitamin A Compound, Best Practice
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia
Interventions
Golidocitinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Non Hodgkin Lymphoma
Interventions
Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
Completed No phase listed Observational Accepts healthy volunteers

ImmuneRACE - Immune Response Action to COVID-19 Events

NCT04494893
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Adaptive Biotechnologies
Industry
Eligibility
18 Years to 89 Years
Enrollment
808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Adults With or Without Liver Damage

NCT05976321
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Conditions
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions
cisplatin, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI, GDC -0941
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more
Conditions
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection
Drug · Procedure · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Healthy
Interventions
Embibatinib, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Millcreek, Utah
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions
ENS-002
Biological
Lead sponsor
Concerto Biosciences
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Hollywood, Florida • Beverly, Massachusetts • Austin, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

XmAb5871 Bioavailability Study

NCT02867098
Conditions
Healthy Volunteers
Interventions
XmAb5871
Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Glendale, California
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
Interventions
Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more